Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1

Conditions

Sarcoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 95Specimen Handling 79Magnetic Resonance Spectroscopy 70Carboplatin 59Cisplatin 56Biopsy 56Nivolumab 51Radiotherapy 47Cyclophosphamide 44Paclitaxel 43Radiation 36durvalumab 33Gemcitabine 31olaparib 30Dexamethasone 30Etoposide 29Doxorubicin 28atezolizumab 26Taxes 25Rituximab 25Docetaxel 25Ipilimumab 24Bevacizumab 24Vincristine 23Lenalidomide 23Pemetrexed 22Cytarabine 22X-Rays 21Radiotherapy, Intensity-Modulated 21Prednisone 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × epacadostat × 90 days × Clear all
NCT03260894 2026-05-22

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

Incyte Corporation

Phase 3 Completed
129 enrolled 13 charts
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT03414229 2026-04-23

A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
30 enrolled 11 charts
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡